Cargando…
Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy
BACKGROUND: Although achieving pathological complete response (pCR) and near-pathological complete response (near-pCR) after neoadjuvant chemotherapy (NAC) in breast cancer predicts a better outcome, some patients still experience recurrence. The aim of our study was to investigate the predictive fa...
Autores principales: | Qian, Xiaoyan, Xiu, Meng, Li, Qing, Wang, Jiayu, Fan, Ying, Luo, Yang, Cai, Ruigang, Li, Qiao, Chen, Shanshan, Yuan, Peng, Ma, Fei, Xu, Binghe, Zhang, Pin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582118/ https://www.ncbi.nlm.nih.gov/pubmed/36276123 http://dx.doi.org/10.3389/fonc.2022.1019925 |
Ejemplares similares
-
Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer
por: Han, Yiqun, et al.
Publicado: (2021) -
Tailoring neoadjuvant chemotherapy for patients with breast cancer who have achieved pathologic complete response
por: Li, Xianjun, et al.
Publicado: (2020) -
Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020) -
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
por: Zhang, Pin, et al.
Publicado: (2016) -
Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy
por: Acevedo, Francisco, et al.
Publicado: (2022)